In a deal that could total about $602 million, Syndax Pharmaceuticals Inc. will collaborate with Incyte Corp. to develop and develop axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. Syndax is to receive $117 million up front, a $35 million equity investment and could bring in another $350 million in regulatory, development and commercial milestone payments.